Retatrutide vs CagriSema: Research Compared

Short answer

The two candidates are often mentioned together because both are late-stage investigational metabolic compounds in large clinical programmes. They are, however, quite different in design. Retatrutide is one engineered peptide that engages three separate receptor pathways. CagriSema is a co-formulation that pairs two distinct peptides with different parent mechanisms. This guide contrasts only mechanism and trial stage, in neutral terms, and makes no claims about outcomes, dosing or suitability for any person.

What retatrutide is

Retatrutide, also known by the development code LY3437943, is an investigational compound associated with Eli Lilly. In the published literature it is described as a once-weekly single-molecule triple agonist. That means one engineered peptide is designed to activate three receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.

The triple-agonist description is the defining feature that distinguishes retatrutide from earlier single-receptor and dual-receptor candidates. Because all three activities sit within one molecule, there is no separate second component to co-formulate or dose. In this guide it is treated strictly as a research chemical and an investigational candidate, not as a therapeutic product.

How retatrutide is described in the literature

• Single engineered peptide (one molecule)
• Reported to act on three receptors: GIP, GLP-1 and glucagon
• Development code LY3437943, associated with Eli Lilly
• Described as a once-weekly investigational candidate

What CagriSema is

CagriSema is an investigational product associated with Novo Nordisk. Unlike retatrutide, it is not a single molecule. It is a fixed-dose combination of two separate peptides supplied together: cagrilintide, described as a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist.

An amylin analogue works on a different pathway from a GLP-1 receptor agonist, so the combination pairs two mechanisms in one co-formulation. This is an important distinction when reading about CagriSema: the GLP-1 component, semaglutide, is a well-known molecule in its own right, while the amylin analogue component and the specific CagriSema combination are a separate matter. See the registered-medicine note below for why that difference matters in Australia.

How CagriSema is described in the literature

• A fixed-dose combination, not a single molecule
• Cagrilintide: a long-acting amylin analogue
• Semaglutide: a GLP-1 receptor agonist
• Associated with Novo Nordisk, described as a once-weekly investigational combination

Mechanism of action, side by side

The clearest way to contrast the two is by counting molecules and receptor pathways. Retatrutide is one molecule reaching three receptors. CagriSema is two molecules reaching two parent pathways (amylin and GLP-1). Both overlap on GLP-1 activity, but they diverge elsewhere: retatrutide adds GIP and glucagon receptor activity within the same peptide, while CagriSema adds amylin-pathway activity through a second, separate peptide.

Neither description here is a statement about effect, benefit or safety. Receptor pharmacology in published registrations describes what a compound is designed to bind, not what it will do in any individual. The mechanisms are summarised below purely as a structural comparison.

Structural comparison

• Retatrutide: 1 molecule, 3 receptors (GIP + GLP-1 + glucagon)
• CagriSema: 2 molecules, 2 parent pathways (amylin analogue + GLP-1 receptor agonist)
• Shared ground: both engage GLP-1 receptor activity
• Key difference: retatrutide is a single triple agonist; CagriSema is a co-formulation of two peptides

Clinical trial stage

Both candidates sit within large late-stage clinical programmes, according to published trial registrations and company statements. Retatrutide is studied in the TRIUMPH Phase 3 programme. CagriSema is studied in the REDEFINE Phase 3 programme. Being in Phase 3 means a compound is still investigational and under study; it does not mean the compound is approved.

As at writing, retatrutide has not been submitted for registration in Australia and is not approved by any regulator. CagriSema has been the subject of a regulatory submission overseas, reported in the United States in late 2025, but had not received approval from any regulator as at writing and is not registered as CagriSema on the Australian Register of Therapeutic Goods. Specific trial numbers, readouts and dates change over time, so treat any figures you read elsewhere as point-in-time and check the primary registrations.

Research compound vs registered medicine

This is the most important distinction for an Australian reader. An approved medicine is listed on the Australian Register of Therapeutic Goods (ARTG) and may be lawfully supplied for therapeutic use through the regulated system. An investigational research compound is neither of those things.

Semaglutide, the GLP-1 component inside CagriSema, is itself available as ARTG-registered medicines under brand names such as Ozempic and Wegovy. That does not mean the CagriSema combination is registered. The combination is a separate investigational product, and as at writing it is not registered as CagriSema on the ARTG. Retatrutide, likewise, is not on the ARTG and is not approved by any regulator.

Keep these separate

• Registered medicine: listed on the ARTG, regulated therapeutic supply
• Investigational combination (CagriSema): not registered as CagriSema on the ARTG as at writing
• Investigational single molecule (retatrutide): not on the ARTG, not approved anywhere as at writing
• A registered component (semaglutide) does not make the combination registered

A note on sport and anti-doping

Metabolic peptides of this kind attract attention from anti-doping authorities. Retatrutide, for example, is covered in substance education material published by Sport Integrity Australia. Athletes and anyone bound by anti-doping rules should not assume an investigational compound is permitted, and should check the current World Anti-Doping Agency Prohibited List and seek guidance from their own sporting body before any decision.

This guide does not provide anti-doping advice. It simply flags that investigational status and competitive-sport eligibility are two separate questions, and that neither can be inferred from the other.

What the evidence shows, honestly

Both compounds are the subject of active, large Phase 3 programmes, and published readouts continue to appear. That volume of study is exactly why neither should be treated as settled. Phase 3 data is still being generated, peer review and regulatory assessment are ongoing, and reported findings for investigational compounds can shift as more trials report.

For that reason this guide deliberately avoids any numeric outcome, efficacy or safety claim, and makes no head-to-head judgement about which candidate is better. The honest position is that both are experimental, both are described in the literature as above, and the definitive picture for each is not yet complete. Anyone researching these compounds should rely on primary trial registrations and regulator statements rather than marketing summaries.

Phase 3 means under study, not approved. An investigational compound is a research question, not a settled answer.

How NovaPeptides frames supply

Where NovaPeptides lists compounds of this type, they are offered strictly for laboratory research use only. Nothing on this page is an offer of a consumer product, a therapeutic good or anything intended for human or animal use. Neither retatrutide nor CagriSema is sold as a product for personal use, and this guide makes no such suggestion.

How supply is framed

• Research use only, for laboratory and in-vitro research
• Independently lab tested, with a Novagen certificate of analysis available
• Ships within Australia from the Gold Coast
• Enquiries handled via WhatsApp

If you are researching either candidate, treat the literature as the authority and confirm regulatory status through the TGA and ARTG directly. This article is educational and neutral, and is not a recommendation to acquire, formulate or use either compound.

Frequently asked questions